Thyrocare Technologies Ltd · NSE:THYROCARE
Thyrocare Technologies — Q3 FY2022 Earnings Presentation
15 slides from Thyrocare Technologies's earnings presentation, Feb 12, 2022
Slide 1: Thyrocare
Thyrocare The Trust. The Truth. February 12, 2022 To, National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeeboy Towers Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400 051 Mumbai- 400 001 Scrip Symbol; THYROCARE Script Code: 539871 Dear Sir/Madam, Sub: Present
Slide 2: Thyrocare Technologies Limited Quarterly Presentation – Dec'21
Thyrocare Technologies Limited Quarterly Presentation – Dec’ 21
Slide 3: API + Thyrocare stronger together – an 8 point agenda
API + Thyrocare stronger together – an 8 point agenda + 1 Serve Pharmeasy Online customers of 2.1 5 Continue to improve our value proposition to our million transacting users1 franchisee network Partner with Retailio network of 87,194 6 Focused brand building on our Health packages 2 pharmacies2 and
Slide 4: Several elements already in pilot / execution phase
Several elements already in pilot / execution phase Cross-sell Collection centers Hospitals Pharmacies Integration of 150+ Pharmeasy 100 Retailio 2 Cities where Thyrocare on collection points retailers on- Aknamed pilot Pharmeasy App initiated (14 cities boarded in 5 cities on-going completed migrat
Slide 5: Several elements already in pilot / execution phase
Several elements already in pilot / execution phase Ease of doing TAT improvement, Addressing churn New Partners business Quality initiatives Test pricing 6+ RPLs initiated 49 new Third Party optimized in Dec, 5 initiatives to improve TAT in providers 588 churned launched for the select regions, int
Slide 6: Key Highlights - Pathology
Key Highlights - Pathology Revenue from operations of Rs. 110 Crore, significantly impacted due to erosion of Revenue from government QoQ business in the earlier period, festivities and general fall in demand historically evidenced in Q3. Revenue 35% ↓ • Revenue from Government contracts alone dippe
Slide 7: In Q3FY22, government business declined, base NOVID business impacted by historical trends
In Q3FY22, government business declined, base NOVID business impacted by historical trends observed due to festivities Thyrocare revenue by sales channel – INR Cr, % 50% • Topline subdued in current 106 quarter after one-time government contract business in last quarter. B2G Excl Pathology revenue c
Slide 8: Patient footfall reduced across all channels due to price increases in Q1
Patient footfall reduced across all channels due to price increases in Q1, which have been corrected in Nov-Dec 2021 Patient count by sales channel (B2B,B2C and B2G) – Lacs, % (25%) 45% • In Q1 – the company had significantly increased prices to the channel which has led 126 B2G to a substantial dec
Slide 9: Degrowth in Patients arrested, starting to see a turnaround in B2B
Degrowth in Patients arrested, starting to see a turnaround in B2B post price corrections in Nov-Dec, significant jump in B2C volumes in Dec NOVID Patient count – ‘000s Price correction of key tests 988 913 914 • Between Apr-21 and Sep- 872 21 prices on key tests were 846 increased by 49% 777 753 •
Slide 10: Preventive care business continued to be in line with pre-covid period
Preventive care business continued to be in line with pre-covid period Revenue by Test Type (Aarogyam vs Others) – INR Cr, % (2%) • Contribution of Aarogyam within Non Covid has Others decreased due to reduced Aarogyam spending on promotion and revision in the incentive structure, which has been cor
Slide 11: Income Statement - Pathology
Income Statement - Pathology Revenue from operations of Rs. 110 Crore, severely impacted due to erosion of covid business and festivities (as historically observed). Revenue for nine month ended 31 December 2021 of Rs. 438 Crore grew by 31 % YOY. Non Covid business sustained at pre-Covid level. Per
Slide 12: Revenue - source
Revenue - source Total Revenue (in crore) Q-Dec20 Q-Sep21 Q-Dec21 132.17 168.74 110.20 • Total reported revenue Diagnostic Services (in crore) Sale of Goods (in crore) mainly consists of revenue from diagnostic services Q-Dec20 Q-Sep21 Q-Dec21 Q-Dec20 Q-Sep21 Q-Dec21 (96%). Revenue from sale 131.90
Slide 13: Income Statement - Radiology
Income Statement - Radiology Radiology business accounted for 6% of reported consolidated revenue of Thyrocare Group in current quarter. Despite of festivities, the footfall at PETCT centres continued to improve in last 2-3 quarters. Income Statement Nuclear Variance (%) Revenue from operations – Re
Slide 14: Patient footfall increased across the centers in the second quarter
Patient footfall increased across the centers in the second quarter Revenue Revenue Radiology Radiology by sales by sales channel channel (Owned/ (Owned/ – INR Cr, %– INR Cr, % Partnered) Partnered) -27% Partnered Owned 10.60 11% (21%) 11.89 4.18 3.12 3.30 7.46 2.74 2.98 1.73 5.22 2.99 3.69 4.30 4.4
Slide 15: Thank You
Thank You Disclaimer This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development,
Thyrocare Technologies — Q3 FY2022 Earnings Presentation on 6ix